Postdoctoral Training in Cancer Genetics

描述(由申请人提供)：这是俄亥俄州立大学综合癌症中心(OSLJCCC)癌症遗传学博士后培训申请的竞争性更新。在第一个资助期内，咨询委员会和培训人员很快认识到培训方案的许多优点以及一些缺点。因此，这一应用代表了一种不断发展的概念，用于培训我们的新类型的癌症研究人员，其中包括我们已经实施或计划在拟议的癌症遗传学培训计划(CG T32)中实施的培训的几个新方面。 培训计划的中心主题和力量保持不变，即在三个癌症地点对受训人员进行基础/翻译共同指导。OSUCCC的40名科学家将联手培训下一代癌症遗传学家，重点是研究和治疗乳腺癌、胃肠癌和造血癌的多学科方法。我们将使用独特的招聘工具，这些工具在上一个资助期被证明非常成功，以吸引和/或留住该项目每年8名有才华的博士后候选人。培训计划认识到，要有效地将知识转化为患者的治疗，需要对癌症发生和发展的基本机制有全面的了解，培训计划已经组建了一支平衡的研究小组，他们拥有遗传学、细胞信号、细胞生物学和肿瘤模型方面的专业知识，并对翻译研究有着浓厚的兴趣和经过验证的记录。将继续实现将基础知识与翻译和/或临床研究相结合的承诺，为学员提供两名共同导师，他们在基础和翻译研究方面具有优势，并拥有不同的专业知识，弥合这两个领域之间的差距。 培训计划的主要新方面包括：1.年度博士后研讨会系列；2.针对每个受训人员并指导/评估申请以帮助他们过渡到独立研究职位(NIH K99/Roo、K01或类似的资助)的拨款撰写研讨会；以及3.增加在翻译和/或临床癌症研究方面具有优势的新的培训教师。通过保持CG T32计划的原有优势和重点，并实施新颖的有针对性的培训方法，拟议的培训计划将创造一个独特的环境，大力鼓励基础科学家冒险从事翻译/临床研究。 相关性：鉴于近年来癌症生物学基础知识的巨大增长，以及癌症治疗领域的明显兴奋，我们感到有义务重新调整我们培训未来癌症研究人员的策略，以满足最终--而不是更早--从社会上根除癌症的期望。我们相信，这一培训计划还将有助于加强培训教师之间已经存在的广泛的正在进行的合作研究，并促进癌症遗传学研究中基本和翻译概念的进一步智力和实践交流。

DESCRIPTION (provided by applicant): This is a competitive renewal of an application for postdoctoral training in cancer genetics at the Ohio State University Comprehensive Cancer Center (OSLJCCC). During the first funding period, the Advisory Committee and training faculty quickly realized the many strengths of the training program as well as some of the weaknesses. This application thus represents an evolving concept for training our new genre of cancer researchers that includes several new aspects to the training that we have implemented or plan to implement in the proposed Cancer Genetics Training Program (CG T32). The central theme and strength of the training program of having basic/translational co-mentoring of trainees in three cancer sites remains intact. Forty scientists at the OSUCCC will join forces to train the next generation of cancer geneticists, with an emphasis on multidisciplinary approaches to the study and treatment of breast, gastro-intestinal and hematopoietic cancers. We will use unique recruiting tools that were proven extraordinarily successful in the last funding period to attract and/or retain eight talented postdoctoral candidates each year of the program. Recognizing that a complete understanding of the basic mechanisms of cancer initiation and progression will be required for the efficient translation of knowledge to the treatment of patients, the training program has compiled a balanced group of investigators with expertise in genetics, cell signaling, cell biology and tumor models, and with an intense interest and a proven record in translational research. The commitment to coupling basic knowledge to translational and/or clinical research will continue to be realized by providing trainees with two co-mentors with strengths in basic and translational research and having divergent expertise, bridging the gap between these two areas. The main new aspects of the training program include 1. an annual postdoctoral symposium series, 2. a grant writing workshop that will be specific to each trainee and guide/evaluate applications aimed to help them transition into independent research positions (NIH K99/ROO, K01 or similar grants), and 3. the addition of new training faculty with strengths in translational and/or clinical cancer research. By maintaining the original strengths and focus of the CG T32 program and implementing novel targeted training approaches, the proposed training program will create a unique setting that strongly encourages basic scientists to venture into translational/clinical research. RELEVANCE: Given the enormous gain of basic knowledge about the biology of cancer in recent years and the palpable excitement in cancer therapeutics, we feel an obligation to retool our strategies of training future cancer researchers to meet the expectation of eventually - sooner rather than later - eradicating cancer from society. We believe that this training program will help to also enhance the extensive ongoing collaborative studies that already exist between training faculty and foster further intellectual and practical exchange of basic and translational concepts to cancer genetics research.